Table 5.
Linear regression models of number of OTUs and ocular inflammation score.
| Variables | Univariable model | Multivariable model | ||
|---|---|---|---|---|
| Coefficient (95% CI) | p-Value | Coefficient (95% CI) | p-Value | |
| Bulbar Conjunctival Hyperaemia score | -1.06 (-2.02, -0.11) | 0.03 | -0.96 (-2.37, 0.45) | 0.17 |
| Age (per decade) | 20.02 (-1.81, 41.85) | 0.07 | 19.54 (-6.68, 45.76) | 0.14 |
| Gender (Female) | 23.65 (-24.75, 72.05) | 0.33 | 12.39 (-37.76, 62.53) | 0.62 |
| Ethnicity (White) | -96.11 (-209.63, 17.41) | 0.10 | -74.55 (-158.08, 8.98) | 0.11 |
| BMI (per 5kg/m2) | -1.68 (-22.80, 19.44) | 0.87 | 2.25 (-28.20, 23.69) | 0.86 |
| Diet (Standard diet) | 12.72 (-84.61, 110.05) | 0.79 | 42.68 (-68.59, 153.96) | 0.44 |
| PPI use (Yes) | -33.39 (-109.32, 42.53) | 0.38 | 12.4 (-86.76, 111.56) | 0.80 |
| Duration of disease from time of diagnosis (per year) | 4.52 (-0.94, 9.98) | 0.10 | -0.66 (-8.28, 6.96) | 0.86 |
| Immunofluorescence status (Positive) | 17.58 (-32.61, 67.78) | 0.48 | -1.58 (-53.65, 56.81) | 0.95 |
| Tetracycline use (current) | -34.52 (-81.74, 12.70) | 0.15 | -39.56 (-89.58, 10.46) | 0.12 |
| Dapsone use (current) | -25.39 (-142.20, 91.42) | 0.66 | -50.08 (-174.55, 74.40) | 0.41 |
| Systemic immunotherapy use (current) | -56.43 (-101.23, -11.63) | 0.02 | -43.21 (-99.81, 13.40) | 0.13 |
Results are from linear regression models. The coefficient represents the increase in the number of OTUs per the stated number of units increase for continuous variables, or for the stated category relative to the reference category for nominal variables. Bold p-values are significant at p<0.05.